Innoviva
INVAPhase 2Innoviva operates a dual-strategy business model, generating significant royalty revenue from its legacy respiratory assets partnered with GlaxoSmithKline (GSK), including TRELEGY ELLIPTA, ANORO ELLIPTA, and RELVAR/BREO ELLIPTA. This financial foundation supports its development of a diversified pipeline in areas of high unmet need, such as oncology and infectious diseases, through subsidiaries like Innoviva Specialty Therapeutics. The company's strategic focus is on acquiring and advancing late-stage clinical assets with the potential for near-term commercialization.
INVA · Stock Price
Historical price data
AI Company Overview
Innoviva operates a dual-strategy business model, generating significant royalty revenue from its legacy respiratory assets partnered with GlaxoSmithKline (GSK), including TRELEGY ELLIPTA, ANORO ELLIPTA, and RELVAR/BREO ELLIPTA. This financial foundation supports its development of a diversified pipeline in areas of high unmet need, such as oncology and infectious diseases, through subsidiaries like Innoviva Specialty Therapeutics. The company's strategic focus is on acquiring and advancing late-stage clinical assets with the potential for near-term commercialization.
Technology Platform
A hybrid business model combining royalty portfolio management with strategic development of novel therapeutics, including a bacteriophage platform for targeting antibiotic-resistant bacterial infections.
Pipeline
4| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Angiotensin-II | Vasodilatory Shock | Approved | |
| Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Cef... | Mycobacterium Abscessus Pulmonary Disease | Phase 2 | |
| Eravacycline 2mg/kg + Eravacycline 1.5mg/kg | Complicated Intra-abdominal Infections (cIAI) | Phase 2 | |
| Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Sul... | Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC) | Phase 1 |
Funding History
1Opportunities
Risk Factors
Competitive Landscape
In respiratory, competes with AstraZeneca, Boehringer Ingelheim, and Novartis via its GSK-partnered products. In infectious disease, SUL-DUR competes with older polymyxin regimens, while its phage therapies would compete in a nascent field against other antibiotic and phage developers. Differentiation is based on novel mechanisms of action and targeting drug-resistant pathogens.